Spatiotemporal co-dependency between macrophages and exhausted CD8+ T cells in cancer. Read more about Spatiotemporal co-dependency between macrophages and exhausted CD8+ T cells in cancer.
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Read more about Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.
Toward a better understanding of T cells in cancer. Read more about Toward a better understanding of T cells in cancer.
Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy. Read more about Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy.
Stepwise evolution of therapy resistance in AML. Read more about Stepwise evolution of therapy resistance in AML.
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Read more about Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.
NRF2 activates macropinocytosis upon autophagy inhibition. Read more about NRF2 activates macropinocytosis upon autophagy inhibition.
Melanoma models for the next generation of therapies. Read more about Melanoma models for the next generation of therapies.
